This is the old version of SRDR. The next, SRDRplus is available! Registration of your SRDRPlus account is free and approval is automatic. Click Here to register an SRDRPlus account.

  • Home
  • Published Projects
  • Registries
Advanced Search

Study Preview



Study Title and Description

Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials.-A



Key Questions Addressed
4 KEY QUESTION 4 KQ 4: What are the effects, comparative effects, and harms of pharmacological interventions (e.g., mesalamine), non-pharmacological interventions (e.g., medical nutrition therapy), and elective surgery to prevent recurrent diverticulitis? • Do the (comparative) effects and harms vary by patient characteristics, course of illness, or other factors?
  • Comments Comments (
    0
    ) |
  • Post/View

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials.-A
Author Raskin JB., Kamm MA., Jamal MM., Márquez J., Melzer E., Schoen RE., Szalóki T., Barrett K., Streck P.
Country University of Miami Miller School of Medicine, Miami, Florida. Electronic address: JRaskin@med.miami.edu.
Year 2014
Numbers Pubmed ID: 25038431

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Extraction Form for KQs 2 and 4
Arms
Number Title Description Comments
1 Placebo
  • Comments Comments (
    0
    ) |
2 Pharm: 5-ASA (1.2 g/d)
  • Comments Comments (
    0
    ) |
3 Pharm: 5-ASA (2.4 g/d)
  • Comments Comments (
    0
    ) |
4 Pharm: 5-ASA (4.8 g/d)
  • Comments Comments (
    0
    ) |

Design Details
Question... Follow Up Answer Follow-up Answer
Specific KQ KQ 2b: Antibiotics (acute)
  • Comments Comments (
    0
    ) |
KQ 2b: Antibiotics (acute)
  • Comments Comments (
    0
    ) |
KQ 2b: Antibiotics (acute)
  • Comments Comments (
    0
    ) |
Study Design RCT
  • Comments Comments (
    0
    ) |
RCT
  • Comments Comments (
    0
    ) |
RCT
  • Comments Comments (
    0
    ) |
Country USA
  • Comments Comments (
    0
    ) |
UK
  • Comments Comments (
    0
    ) |
Other ... Argentina, Australia, Colombia, France, India, Israel, New Zealand, Spain, Sweden (from NCT)
  • Comments Comments (
    0
    ) |
Funder Industry (fully or in part)
  • Comments Comments (
    0
    ) |
Study name PREVENT1
  • Comments Comments (
    0
    ) |
Associated articles
  • Comments Comments (
    0
    ) |
ClinicalTrials.gov identifier NCT00545740
  • Comments Comments (
    0
    ) |
Start and end years of the Study 2007
  • Comments Comments (
    0
    ) |
2013
  • Comments Comments (
    0
    ) |
Inclusion criteria >= 18 years. 1 documented episodes of acute diverticulitis in the previous 24 months that resolved w/o colonic resection, and w/o signs/symptoms of diverticulitis within 6 wks of enrollment. Confirmation of diverticulosis via endoscopic evaluation of the sigmoid colon w/ at >= 3 diverticula noted.
  • Comments Comments (
    0
    ) |
Exclusion criteria Previous colorectal surgery, surgical intervention for diverticular disease (w/ exceptions of hemorrhoidectomy, colonic removal of polyps, appendectomy); no complicated diverticulitis (no perforation or fistulization present on CT); right-sided diverticulosis only; active peptic ulcer disease; history or current IBD. Active irritable bowel syndrome, GI bleeding, endometriosis or dysmenorrhea (6 months before baseline), or current or historical use of biologic drugs, immunomodulators, or systemic/rectal steroids (6 wks before baseline) (from NCT).
  • Comments Comments (
    0
    ) |
Specific population? No (all comers)
  • Comments Comments (
    0
    ) |
Was diverticulitis diagnosed with CT? CT
  • Comments Comments (
    0
    ) |
If NRCS, what analytic method was used to account for differences between study arms?
  • Comments Comments (
    0
    ) |
How was diverticulitis diagnosed Endoscopic confirmation of >= 3 diverticula was required. CT, MRI, ultrasound, colonoscopy, sigmoidoscopy, and barium enema.
  • Comments Comments (
    0
    ) |
Note/Comment about Design (or overall study)
  • Comments Comments (
    0
    ) |


Baseline Characteristics
Question Placebo Pharm: 5-ASA (1.2 g/d) Pharm: 5-ASA (2.4 g/d) Pharm: 5-ASA (4.8 g/d) Total Comments
AnswerFollow-up AnswerFollow-up AnswerFollow-up AnswerFollow-up AnswerFollow-up
Participant race/ethnicity characteristics Male 48.3 Male 55.2 Male 51.7 Male 52.7 Male 52.8
  • Comments Comments (
    0
    ) |
White 83 White 79 White 83.2 White 82 White 81.8
  • Comments Comments (
    0
    ) |
Black 1.4 Black 3.5 Black 1.4 Black 2.7 Black 2.2
  • Comments Comments (
    0
    ) |
Hispanic/Latino 20.4 Hispanic/Latino 25.9 Hispanic/Latino 25.9 Hispanic/Latino 21.3 Hispanic/Latino 23.3
  • Comments Comments (
    0
    ) |
Asian 2.7 Asian 2.8 Asian 2.1 Asian 2 Asian 2.4
  • Comments Comments (
    0
    ) |
Other (or specific) race/ethnicity 1 - include race/ethnicity in parentheses 12.9 Other (or specific) race/ethnicity 1 - include race/ethnicity in parentheses 14.7 Other (or specific) race/ethnicity 1 - include race/ethnicity in parentheses 13.3 Other (or specific) race/ethnicity 1 - include race/ethnicity in parentheses 13.3 Other (or specific) race/ethnicity 1 - include race/ethnicity in parentheses 13.6
  • Comments Comments (
    0
    ) |
Participant Age - Continuous data (in years) Mean 57.1 Mean 55.1 Mean 54.5 Mean 54.5 Mean 55.3
  • Comments Comments (
    0
    ) |
SD 10.42 SD 11.11 SD 11.96 SD 11.93 SD 11.39
  • Comments Comments (
    0
    ) |
Participant Age - Categorical data No data entered.
Participants with Un/Complicated Diverticulitis No data entered.
Specific Complications of Diverticulitis No data entered.
Number of Prior Episodes of Diverticulitis (categorical) 0 0 0 0 0 1.4 0 0 0 0.3
  • Comments Comments (
    0
    ) |
1 60.5 1 55.9 1 60.1 1 56 1 58.1
  • Comments Comments (
    0
    ) |
2 23.1 2 29.4 2 22.4 2 26.7 2 25.4
  • Comments Comments (
    0
    ) |
Other_1 (include definition in %) 4-5: 4.8 Other_1 (include definition in %) 4-5: 5.6 Other_1 (include definition in %) 4-5: 7.7 Other_1 (include definition in %) 4-5: 4.0 Other_1 (include definition in %) 4-5: 5.5
  • Comments Comments (
    0
    ) |
Other_2 (include definition in %) 6-10: 2.7 Other_2 (include definition in %) 6-10: 1.4 Other_2 (include definition in %) 6-10: 1.4 Other_2 (include definition in %) 6-10: 2.7 Other_2 (include definition in %) 6-10: 2.1
  • Comments Comments (
    0
    ) |
History of (Prior) Complicated Diverticulitis No data entered.
KQ 4: Time Since Last Episode of Diverticulitis Median 14.7 weeks Median 12 weeks Median 12.9 weeks Median 13.6 weeks Median 13 weeks
  • Comments Comments (
    0
    ) |
Range 0-94 weeks Range 1-419 weeks Range 1-93 weeks Range 1-114 weeks Range 0-419 weeks
  • Comments Comments (
    0
    ) |
Note/Comment about baseline characteristics No data entered.
Number of Prior Episodes of Diverticulitis (continuous) No data entered.



Results & Comparisons


Results Data
P-Value
Outcome: No recurrence      Population: All Participants Between-Arm Comparisons
Time Point Measure Placebo Pharm: 5-ASA (1.2 g/d) Pharm: 5-ASA (2.4 g/d) Pharm: 5-ASA (4.8 g/d) Comparison Measure Placebo vs. Pharm: 5-ASA (1.2 g/d) Placebo vs. Pharm: 5-ASA (2.4 g/d) Placebo vs. Pharm: 5-ASA (4.8 g/d)


104 weeks

 N Analyzed 147 143 143 150 0.780 0.741 0.047
Counts 95 89 90 79
Percentage 64.6 62.2 62.9 52.7
Outcome: Adverse event - any      Population: All Participants
Time Point Measure Placebo Pharm: 5-ASA (1.2 g/d) Pharm: 5-ASA (2.4 g/d) Pharm: 5-ASA (4.8 g/d)


104 weeks

 N Analyzed 147 143 143 150
Counts 112 109 106 101
Percentage 76.2 76.2 74.1 67.3
Outcome: AE - Serious (SAE)      Population: All Participants
Time Point Measure Placebo Pharm: 5-ASA (1.2 g/d) Pharm: 5-ASA (2.4 g/d) Pharm: 5-ASA (4.8 g/d)


104 weeks

 N Analyzed 147 [1] 143 143 150
Counts 16 16 15 18
Percentage 10.9 11.19 10.49 12
Footnotes
1. From NCT
Outcome: AE - Sepsis (CD IV)      Population: All Participants
Time Point Measure Placebo Pharm: 5-ASA (1.2 g/d) Pharm: 5-ASA (2.4 g/d) Pharm: 5-ASA (4.8 g/d)


104 weeks

 N Analyzed 147 [1] 143 143 150
Counts 0 1 0 1
Percentage 0 0.7 0 0.67
Footnotes
1. From NCT
Outcome: AE - Major cardiac event (CD IV)      Population: All Participants
Time Point Measure Placebo Pharm: 5-ASA (1.2 g/d) Pharm: 5-ASA (2.4 g/d) Pharm: 5-ASA (4.8 g/d)


104 weeks

 N Analyzed 147 [1] 143 143 150
Counts 2 1 0 0
Percentage 1.36 0.70 0 0
Footnotes
1. From NCT
Outcome: AE - Infection requiring Abx (CD II)      Population: All Participants
Time Point Measure Placebo Pharm: 5-ASA (1.2 g/d) Pharm: 5-ASA (2.4 g/d) Pharm: 5-ASA (4.8 g/d)


104 weeks

 N Analyzed 147 143 143 150
Counts 17 14 12 8
Percentage 11.6 9.8 8.4 5.3


Quality Dimensions
Dimension Value Notes Comments
Q14: Cochrane - Random sequence generation (selection bias): Selection bias (biased allocation to interventions) due to inadequate generation of a randomized sequence Low Patients were randomly assigned in a 1:1:1:1 ratio.
  • Comments Comments (
    0
    ) |
Q15: Cochrane - Allocation concealment (selection bias): Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment Low Intervention assigned to each patient was determined by a computer-generated fixed-block randomization schedule.
  • Comments Comments (
    0
    ) |
Q16: Cochrane - Blinding of participants (performance bias): Performance bias due to knowledge of the allocated interventions by participants during the study Low Double-blind
  • Comments Comments (
    0
    ) |
Q17: Cochrane - Blinding of personnel/ care providers (performance bias): Performance bias due to knowledge of the allocated interventions by personnel/care providers during the study. Low Double-blind
  • Comments Comments (
    0
    ) |
Q18: Cochrane - FOR OBJECTIVE OUTCOMES - Blinding of outcome assessor (detection bias): Detection bias due to knowledge of the allocated interventions by outcome assessors. Yes Low risk of detection bias because outcome assessors were blinded (NCT).
  • Comments Comments (
    0
    ) |
Q20: Cochrane - Incomplete outcome data (attrition bias): Attrition bias due to amount, nature or handling of incomplete outcome data Low Patients who completely withdrew from the study before week 104 without a protocol-defined recurrence of diverticulitis were considered dropouts and assumed to be treatment failures for the intention-to-treat primary analysis. Additional sensitivity analyses were performed using different methods for handling dropouts. Reasons for withdrawals are provided in Figure 1.
  • Comments Comments (
    0
    ) |
Q21: Cochrane - Selective Reporting (reporting bias): Reporting bias due to selective outcome reporting Low Study protocol is unavailable, but expected outcomes were reported.
  • Comments Comments (
    0
    ) |
Q22: Cochrane - Other Bias: Bias due to problems not covered elsewhere in the table. If yes, describe them in the Notes. Low Study appears to be free of other sources of bias.
  • Comments Comments (
    0
    ) |
Q1: ROBINS-I 1.1 Is there potential for confounding of the effect of intervention in this study?
  • Comments Comments (
    0
    ) |
Q3: ROBINS-I 1.4. Did the authors use an appropriate analysis method that controlled for all the important confounding domains?
  • Comments Comments (
    0
    ) |
Q4: ROBINS-I 1.5. If Y/PY to 1.4: Were confounding domains that were controlled for measured validly and reliably by the variables available in this study?
  • Comments Comments (
    0
    ) |
Q5: ROBINS-I 1.6. Did the authors control for any post-intervention variables that could have been affected by the intervention?
  • Comments Comments (
    0
    ) |
Q6: ROBINS-I - Risk of bias judgement for BIAS DUE TO CONFOUNDING
  • Comments Comments (
    0
    ) |
Q7: ROBINS-I 2.1. Was selection of participants into the study (or into the analysis) based on participant characteristics observed after the start of intervention?
  • Comments Comments (
    0
    ) |
Q8: ROBINS-I 2.2. If Y/PY to 2.1: Were the post-intervention variables that influenced selection likely to be associated with intervention?
  • Comments Comments (
    0
    ) |
Q9: ROBINS-I 2.3 If Y/PY to 2.2: Were the post-intervention variables that influenced selection likely to be influenced by the outcome or a cause of the outcome?
  • Comments Comments (
    0
    ) |
Q10: ROBINS-I 2.4. Do start of follow-up and start of intervention coincide for most participants?
  • Comments Comments (
    0
    ) |
Q12: ROBINS-I 2.5. If Y/PY to 2.2 and 2.3, or N/PN to 2.4: Were adjustment techniques used that are likely to correct for the presence of selection biases?
  • Comments Comments (
    0
    ) |
Q13: ROBINS-I - Risk of bias judgement for BIAS IN SELECTION OF PARTICIPANTS INTO THE STUDY
  • Comments Comments (
    0
    ) |
Q2: Did the study divide the follow up time of each individual participant into the different interventions?
  • Comments Comments (
    0
    ) |
Q11: Did the start and follow up calendar years coincide for most participants in the study?
  • Comments Comments (
    0
    ) |
Q19: Cochrane - FOR SUBJECTIVE OUTCOMES - Blinding of outcome assessor (detection bias): Detection bias due to knowledge of the allocated interventions by outcome assessors. Yes Low risk of detection bias in patient-reported outcomes because participants were blinded.
  • Comments Comments (
    0
    ) |
Q23: NHLBI - Were eligibility/selection criteria for the study population prespecified and clearly described?
  • Comments Comments (
    0
    ) |
Q24: NHLBI - Was the test/service/intervention clearly described and delivered consistently across the study population?
  • Comments Comments (
    0
    ) |
Q25: NHLBI - Were the outcome measures prespecified, clearly defined, valid, reliable, and assessed consistently across all study participants?
  • Comments Comments (
    0
    ) |

Quality Rating
No quality rating data was found.